Ultragenyx Pharmaceutical (RARE) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Syndax Pharmaceuticals (SNDX) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 3.5% versus a loss of 49.9%. Over five years, SNDX leads with a -8.4% price change compared with -81.4% for RARE. Ultragenyx Pharmaceutical is the larger company by market cap ($1.47 billion vs $1.47 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RARE | SNDX |
|---|---|---|
| Share price | $14.96 | $16.51 |
| Market cap | $1.47B | $1.47B |
| 1-day change | +0.44% | -3.05% |
| YTD return | -35.26% | -18.94% |
| 1-year return | -49.93% | +3.53% |
| 5-year return | -81.39% | -8.39% |
| Forward P/E | 22.10 | — |
| EPS (TTM) | $-5.82 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.89 | $25.59 |
| 52-week low | $12.73 | $12.99 |
| Distance from 52-week high | -62.51% | -35.48% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +87.56% | +127.44% |
| Average volume | 3.81M | 1.54M |
| Shares outstanding | 98.59M | 89.30M |
| Employees | 1,371 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SNDX has outperformed RARE by 53.5 percentage points over the past year.
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
RARE vs SNDX FAQ
Which is bigger, Ultragenyx Pharmaceutical or Syndax Pharmaceuticals?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.47B compared with $1.47B for Syndax Pharmaceuticals (SNDX).
Which stock has performed better over the past year, RARE or SNDX?
SNDX returned +3.53% over the past 12 months, compared with -49.93% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Ultragenyx Pharmaceutical and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.